Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Cost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsReceivables - NetShares OutstandingShares Outstanding
Ratios

Myomo (MYO) Cost of Revenue (2017 - 2025)

Myomo filings provide 9 years of Cost of Revenue readings, the most recent being $5.3 million for Q3 2025.

  • On a quarterly basis, Cost of Revenue rose 54.48% to $5.3 million in Q3 2025 year-over-year; TTM through Sep 2025 was $17.4 million, a 59.8% increase, with the full-year FY2024 number at $12.2 million, up 35.32% from a year prior.
  • Cost of Revenue hit $5.3 million in Q3 2025 for Myomo, roughly flat from $5.2 million in the prior quarter.
  • In the past five years, Cost of Revenue ranged from a high of $5.3 million in Q3 2025 to a low of $623152.0 in Q1 2021.
  • Median Cost of Revenue over the past 5 years was $2.3 million (2023), compared with a mean of $2.3 million.
  • The widest YoY moves for Cost of Revenue: up 115.24% in 2021, down 9.76% in 2021.
  • Myomo's Cost of Revenue stood at $909175.0 in 2021, then surged by 55.52% to $1.4 million in 2022, then soared by 66.43% to $2.4 million in 2023, then surged by 57.1% to $3.7 million in 2024, then skyrocketed by 42.13% to $5.3 million in 2025.
  • The last three reported values for Cost of Revenue were $5.3 million (Q3 2025), $5.2 million (Q2 2025), and $3.2 million (Q1 2025) per Business Quant data.